| Alfred Dennis Belen Iii, MD | |
|
3980 Sheridan Dr Ste 500, Dent Neurologic Group, Amherst, NY 14226 | |
| (716) 250-2000 | |
| (716) 250-2040 |
| Full Name | Alfred Dennis Belen Iii |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 19 Years |
| Location | 3980 Sheridan Dr Ste 500, Amherst, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386776847 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 2009-00922 (North Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trinity Medical Wny Pc | 5193907517 | 128 |
| Inland Psychiatric Medical Group Inc | 9436062312 | 84 |
News Archive
Cipher Pharmaceuticals Inc. today announced that it has received an Acceptance Review Notification for its 510(k) submission for Dermadexin to the U.S. Food & Drug Administration.
Viral diseases are still one of the biggest challenges to medical science. Thanks to thousands of years of co-evolution with humans, their ability to harness the biology of their human hosts to survive and thrive makes them very difficult to target with medical treatment.
Allergan plc and Merck, known as MSD outside the United States and Canada, today announced that they have entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine, subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).
Bill and Melinda Gates announced Friday during the World Economic Forum in Davos, Switzerland, that their foundation would commit $10 billion over the next decade to research, develop and deliver vaccines for the world's poorest countries, the New York Times reports (McNeil, 1/29). The Gateses "said they hope the commitment would spur support by governments, corporations, and other donors for vaccinations efforts," the Chronicle of Philanthropy writes (Wilhelm, 1/29).
Researchers have identified a potential biological mechanism that could explain why oral contraceptives may be less effective at preventing pregnancy in obese women, as some epidemiological studies have indicated.
› Verified 1 days ago
| Entity Name | Kaleida Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366473183 PECOS PAC ID: 7810805280 Enrollment ID: O20031105000212 |
News Archive
Cipher Pharmaceuticals Inc. today announced that it has received an Acceptance Review Notification for its 510(k) submission for Dermadexin to the U.S. Food & Drug Administration.
Viral diseases are still one of the biggest challenges to medical science. Thanks to thousands of years of co-evolution with humans, their ability to harness the biology of their human hosts to survive and thrive makes them very difficult to target with medical treatment.
Allergan plc and Merck, known as MSD outside the United States and Canada, today announced that they have entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine, subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).
Bill and Melinda Gates announced Friday during the World Economic Forum in Davos, Switzerland, that their foundation would commit $10 billion over the next decade to research, develop and deliver vaccines for the world's poorest countries, the New York Times reports (McNeil, 1/29). The Gateses "said they hope the commitment would spur support by governments, corporations, and other donors for vaccinations efforts," the Chronicle of Philanthropy writes (Wilhelm, 1/29).
Researchers have identified a potential biological mechanism that could explain why oral contraceptives may be less effective at preventing pregnancy in obese women, as some epidemiological studies have indicated.
› Verified 1 days ago
| Entity Name | University Of Rochester |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710226824 PECOS PAC ID: 5799699088 Enrollment ID: O20031201000019 |
News Archive
Cipher Pharmaceuticals Inc. today announced that it has received an Acceptance Review Notification for its 510(k) submission for Dermadexin to the U.S. Food & Drug Administration.
Viral diseases are still one of the biggest challenges to medical science. Thanks to thousands of years of co-evolution with humans, their ability to harness the biology of their human hosts to survive and thrive makes them very difficult to target with medical treatment.
Allergan plc and Merck, known as MSD outside the United States and Canada, today announced that they have entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine, subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).
Bill and Melinda Gates announced Friday during the World Economic Forum in Davos, Switzerland, that their foundation would commit $10 billion over the next decade to research, develop and deliver vaccines for the world's poorest countries, the New York Times reports (McNeil, 1/29). The Gateses "said they hope the commitment would spur support by governments, corporations, and other donors for vaccinations efforts," the Chronicle of Philanthropy writes (Wilhelm, 1/29).
Researchers have identified a potential biological mechanism that could explain why oral contraceptives may be less effective at preventing pregnancy in obese women, as some epidemiological studies have indicated.
› Verified 1 days ago
| Entity Name | Kenmore Mercy Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770598104 PECOS PAC ID: 7517870462 Enrollment ID: O20040319000138 |
News Archive
Cipher Pharmaceuticals Inc. today announced that it has received an Acceptance Review Notification for its 510(k) submission for Dermadexin to the U.S. Food & Drug Administration.
Viral diseases are still one of the biggest challenges to medical science. Thanks to thousands of years of co-evolution with humans, their ability to harness the biology of their human hosts to survive and thrive makes them very difficult to target with medical treatment.
Allergan plc and Merck, known as MSD outside the United States and Canada, today announced that they have entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine, subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).
Bill and Melinda Gates announced Friday during the World Economic Forum in Davos, Switzerland, that their foundation would commit $10 billion over the next decade to research, develop and deliver vaccines for the world's poorest countries, the New York Times reports (McNeil, 1/29). The Gateses "said they hope the commitment would spur support by governments, corporations, and other donors for vaccinations efforts," the Chronicle of Philanthropy writes (Wilhelm, 1/29).
Researchers have identified a potential biological mechanism that could explain why oral contraceptives may be less effective at preventing pregnancy in obese women, as some epidemiological studies have indicated.
› Verified 1 days ago
| Entity Name | Mount St. Marys Hospital Of Niagara Falls |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043394745 PECOS PAC ID: 4082523790 Enrollment ID: O20040403000031 |
News Archive
Cipher Pharmaceuticals Inc. today announced that it has received an Acceptance Review Notification for its 510(k) submission for Dermadexin to the U.S. Food & Drug Administration.
Viral diseases are still one of the biggest challenges to medical science. Thanks to thousands of years of co-evolution with humans, their ability to harness the biology of their human hosts to survive and thrive makes them very difficult to target with medical treatment.
Allergan plc and Merck, known as MSD outside the United States and Canada, today announced that they have entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine, subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).
Bill and Melinda Gates announced Friday during the World Economic Forum in Davos, Switzerland, that their foundation would commit $10 billion over the next decade to research, develop and deliver vaccines for the world's poorest countries, the New York Times reports (McNeil, 1/29). The Gateses "said they hope the commitment would spur support by governments, corporations, and other donors for vaccinations efforts," the Chronicle of Philanthropy writes (Wilhelm, 1/29).
Researchers have identified a potential biological mechanism that could explain why oral contraceptives may be less effective at preventing pregnancy in obese women, as some epidemiological studies have indicated.
› Verified 1 days ago
| Entity Name | Mercy Hospital Of Buffalo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164464921 PECOS PAC ID: 8729991666 Enrollment ID: O20040702001253 |
News Archive
Cipher Pharmaceuticals Inc. today announced that it has received an Acceptance Review Notification for its 510(k) submission for Dermadexin to the U.S. Food & Drug Administration.
Viral diseases are still one of the biggest challenges to medical science. Thanks to thousands of years of co-evolution with humans, their ability to harness the biology of their human hosts to survive and thrive makes them very difficult to target with medical treatment.
Allergan plc and Merck, known as MSD outside the United States and Canada, today announced that they have entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine, subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).
Bill and Melinda Gates announced Friday during the World Economic Forum in Davos, Switzerland, that their foundation would commit $10 billion over the next decade to research, develop and deliver vaccines for the world's poorest countries, the New York Times reports (McNeil, 1/29). The Gateses "said they hope the commitment would spur support by governments, corporations, and other donors for vaccinations efforts," the Chronicle of Philanthropy writes (Wilhelm, 1/29).
Researchers have identified a potential biological mechanism that could explain why oral contraceptives may be less effective at preventing pregnancy in obese women, as some epidemiological studies have indicated.
› Verified 1 days ago
| Entity Name | Trinity Medical Wny Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295043149 PECOS PAC ID: 5193907517 Enrollment ID: O20110307000596 |
News Archive
Cipher Pharmaceuticals Inc. today announced that it has received an Acceptance Review Notification for its 510(k) submission for Dermadexin to the U.S. Food & Drug Administration.
Viral diseases are still one of the biggest challenges to medical science. Thanks to thousands of years of co-evolution with humans, their ability to harness the biology of their human hosts to survive and thrive makes them very difficult to target with medical treatment.
Allergan plc and Merck, known as MSD outside the United States and Canada, today announced that they have entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine, subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).
Bill and Melinda Gates announced Friday during the World Economic Forum in Davos, Switzerland, that their foundation would commit $10 billion over the next decade to research, develop and deliver vaccines for the world's poorest countries, the New York Times reports (McNeil, 1/29). The Gateses "said they hope the commitment would spur support by governments, corporations, and other donors for vaccinations efforts," the Chronicle of Philanthropy writes (Wilhelm, 1/29).
Researchers have identified a potential biological mechanism that could explain why oral contraceptives may be less effective at preventing pregnancy in obese women, as some epidemiological studies have indicated.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alfred Dennis Belen Iii, MD 3980 Sheridan Dr, Amherst, NY 14226-1727 Ph: (716) 250-2000 | Alfred Dennis Belen Iii, MD 3980 Sheridan Dr Ste 500, Dent Neurologic Group, Amherst, NY 14226 Ph: (716) 250-2000 |
News Archive
Cipher Pharmaceuticals Inc. today announced that it has received an Acceptance Review Notification for its 510(k) submission for Dermadexin to the U.S. Food & Drug Administration.
Viral diseases are still one of the biggest challenges to medical science. Thanks to thousands of years of co-evolution with humans, their ability to harness the biology of their human hosts to survive and thrive makes them very difficult to target with medical treatment.
Allergan plc and Merck, known as MSD outside the United States and Canada, today announced that they have entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine, subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).
Bill and Melinda Gates announced Friday during the World Economic Forum in Davos, Switzerland, that their foundation would commit $10 billion over the next decade to research, develop and deliver vaccines for the world's poorest countries, the New York Times reports (McNeil, 1/29). The Gateses "said they hope the commitment would spur support by governments, corporations, and other donors for vaccinations efforts," the Chronicle of Philanthropy writes (Wilhelm, 1/29).
Researchers have identified a potential biological mechanism that could explain why oral contraceptives may be less effective at preventing pregnancy in obese women, as some epidemiological studies have indicated.
› Verified 1 days ago
Syed Jaffri, M.D.,M.R.C.,PSYCH. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2800 Sweet Home Rd, #8, Amherst, NY 14228 Phone: 716-691-0639 Fax: 716-691-0410 | |
Horacio Capote, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3980 Sheridan Dr Ste 500, Dent Neurologic Group, Llp, Amherst, NY 14226 Phone: 716-250-2000 Fax: 716-636-1365 | |
Ms. Jesslyn Lee Weber, PA-C Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3980 Sheridan Dr, Amherst, NY 14226 Phone: 716-250-2000 | |
Maria T Cartagena, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 85 Bryant Woods S, Amherst, NY 14228 Phone: 716-689-3333 Fax: 716-689-9866 | |
Maria K Nickolova, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 85 Bryant Woods S, Amherst, NY 14228 Phone: 716-689-3333 Fax: 716-689-9866 | |
Dr. Cynthia Beatty, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 300 Essjay Rd, Amherst, NY 14221 Phone: 716-932-6080 | |
Dr. Howard C Wilinsky, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 4955 N Bailey Ave, Ste 130, Amherst, NY 14226 Phone: 716-835-1246 Fax: 716-835-0396 |